Trimethoprim-sulfamethoxazole-induced lung injury: a case report

Peiqi Huang1,2, Kai-Qian Kam2,3,4,5, Yi Hua Tan2,4,5,6

  • 1Department of Neonatology, KK Women's & Children's Hospital, Singapore, Singapore.

Translational Pediatrics
|December 22, 2023
PubMed
Abstract

Insights

Trimethoprim-sulfamethoxazole (TMP-SMX) can cause rare but serious lung injury (DLI) in children. Early diagnosis and drug withdrawal are key to recovery, though more research is needed.

Area of Science:

  • Pediatric Pulmonology
  • Pharmacovigilance
  • Drug-Induced Lung Injury

Background:

  • Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely used antibiotic with known cutaneous side effects.
  • Lung toxicity from TMP-SMX, including hypersensitivity pneumonitis and acute respiratory distress syndrome, is uncommon.
  • TMP-SMX-associated drug-induced lung injury (DLI) is rarely reported in children, with poorly understood pathogenesis and diagnostic challenges.